Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.”In the company’s words, NCT03176186 on ClinicalTrials.gov
- Tested for
- Post-Cardiac Arrest Syndrome
- Main trialPhase 3
- “XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \[TTM\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).”In the company’s words, NCT03176186 on ClinicalTrials.gov
Coming up1
- Apr 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Apr 2029 | Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest | |
| Phase 2Authorised | not given | Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026